We have pharmaceutical companies that are constantly trying to expand the indications, expand the number of people who are eligible for a given treatment, because that obviously helps their bottom line.
Tenemos las compañías farmacéuticas que constantemente tratan de ampliar las indicaciones y el número de personas elegibles para un tratamiento dado, porque eso, obviamente, incrementa sus ingresos.